89778-27-8 Toremifene citrate AKSci J10647
 
 
Loading Please Wait...
  J10647    
Toremifene citrate
, 99% (HPLC)
 
Toremifene
(Z)-4-Chloro-1-(4-dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene Citrate
(Z)-2-[4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine Citrate




IDENTITY
CAS Number:89778-27-8
MDL Number:MFCD01729016
MF:C32H36ClNO8
MW:598.08
SPECIFICATIONS & PROPERTIES
Purity:99% (HPLC)
Physical Form:White to off-white powder
Melting Point:158-166°C
Long-Term Storage:Store long-term at 2-8°C
UN #:Not hazmat

BIOLOGICAL INFO
Solubility:DMSO: >10mg/mL
Application(s):Selective estrogen receptor modulator (SERM)
Form:Citrate

REVIEW

 Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, in other words, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor. Toremifene may also inhibit tumor growth through other mechanisms, such as induction of apoptosis, regulation of oncogene expression, and growth factors.

REFERENCES
[1]Price N, Sartor O, Hutson T, Mariani S: Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):211-4.
[2] Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA: Toremifene-a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs. 2006 Mar;15(3):293-305.
[3] Thompson IM: Chemoprevention of prostate cancer: agents and study designs. J Urol. 2007 Sep;178(3 Pt 2):S9-S13. Epub 2007 Jul 20.
[4] Ariazi EA, Ariazi JL, Cordera F, Jordan VC: Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 2006;6(3):181-202.

GHS

Pictograms

Signal Word
Danger

Hazard Statements
H302; H318; H410

Precautionary Statements
P264; P270; P273; P280; P301+P312; P305+P351+P338; P310; P330; P391; P501


Current as of January 19, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Estrogen Receptor Modulators


PubChem